Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.

Adriaan Volkers Tessa StraatmijerMarjolijn DuijvesteinAmber SalesAmit LevranFiona van SchaikP W Jeroen MaljaarsKrisztina GecseCyriel PonsioenJoep GrootjansJurij HanželGreetje TackJeroen JansenFrank HoentjenNanne de BoerSander van der MarelGerard DijkstraBas OldenburgMark LöwenbergAndrea van der MeulenGeert D Haensnull null

Published in: Alimentary pharmacology & therapeutics (2022)

Switching from IV to SC vedolizumab maintenance treatment is effective in patients with CD or UC. However, 9% of patients were switched back to IV vedolizumab due to adverse events or fear of needles.

Keyphrases

ulcerative colitis
end stage renal disease
newly diagnosed
ejection fraction
high dose
peritoneal dialysis